Antithrombotic drugs market has been in full swing again! Recently, Xiansheng Pharmaceutical won the first imitation of edoxaban toluenesulfonate tablets. Kelun Pharmaceutical's 's fundalcano sodium injection and Tianfang Pharmaceutical's 's Agatroban injection were approved and deemed to be passed. m Inner Network data shows that in 2022H1, the sales of terminal antithrombotic drugs in public medical institutions in China exceeded 16 billion yuan, the TOP10 clopidogrel ranked first again, the exclusive variety indobufen tablets rose by 122.30%, and the top five seats in the TOP10 brands were monopolized by foreign-funded enterprises. At present, 20 varieties of antithrombotic drugs have been reviewed, and three varieties are expected to be included in the eighth batch of centralized procurement.
TOP10 antithrombotic drugs! The sales of celebrity drugs were halved, and the exclusive varieties soared by 122%
Antithrombotic drugs are the main category in the cardiovascular and cerebrovascular field. Minnei.com data shows that the terminal sales volume of antithrombotic drugs in China in 2021 exceeded 35 billion yuan in urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as Chinese public medical institutions) exceeded 9.74% year-on-year; the sales volume in the first half of 2022 exceeded 16 billion yuan, a decrease of 4.13% from the same period last year.
Sales of terminal antithrombotic drugs in public medical institutions in China (unit: 10,000 yuan)
Among the top 10 antithrombotic drugs products, the sales of four products, including clopidogrel hydrogensulfate tablets, enoxaparin sodium injection, aspirin enteric-coated tablets, rivaroxaban tablets, all exceeded 1 billion yuan in the six-year period. clopidogrel hydrogensulfate tablets have maintained their position as the "No. 1" with sales of more than 2 billion yuan. It is worth mentioning that enoxaparin sodium injection and aspirin enteric-coated tablets have not been included in the centralized procurement.
From the perspective of sales growth rate, three products showed negative growth. The sales of rivaroxaban tablets included in the fifth batch of centralized procurement fell by 49.95%, and low molecular weight heparin calcium injection fell by 14.11%; 7 products showed positive growth, and the sales of the exclusive variety indobufen tablets rose by 122.30%. The first batch of centralized procurement hit clopidogrel hydrogen sulfate tablets began to stop falling and rebound, and heparin sodium injection and beprost sodium tablets rose by more than 10%.
2022H1 TOP10 terminal antithrombotic drug products for public medical institutions in China
Among the top 10 antithrombotic drug brands, the top five seats are monopolized by foreign-funded enterprises, and Sanofi and Bayer have 2 brands on the list; Sanofi's clopidogrel hydrogen sulfate tablets and Bayer's aspirin enteric-coated tablets ranked first respectively. Second, sales are all over 1 billion yuan; in addition to Sanofi's Polivi, Clopipidol bisulfate tablets from Xinlitai and Lepu Pharmaceutical are also on the list; domestic brands include Changshan Pharmaceutical low-molecular weight heparin calcium injection, Hangzhou Zhongmei East China Pharmaceutical indobufen tablets, and Taide Pharmaceutical sodium tablets.
2022H1 TOP10
9 antithrombotic drugs have been collected in China, and the 10 billion varieties have stopped falling, and 3 more than 1 billion varieties have been beaten
In the six batches of drug procurement carried out by the country, 1, 0, 2, 2, 2, and 3 varieties of antithrombotic drugs have been included in the centralized procurement, among which the specifications of 90mg and 60mg of oral constant-release dosage forms of ticagrelor oral constant-release dosage forms were included in the third and fourth batches of centralized procurement, so there are 9 varieties of antithrombotic drugs that have been collected.
National centralized procurement of antithrombotic drugs
9 varieties, bivaludin for injection is the first antithrombotic drug injection included in the centralized procurement. The seventh batch of antithrombotic drugs adopted are all injections, including fondaparin sodium injection, tirofiban injection, and etibatide injection. Whether the next batch of centralized procurement will be included in heparin preparations is worth paying attention to.
As a star variety in the antithrombotic drug market, clopidogrel ushered in its peak moment in 2018, with terminal sales in public medical institutions in China exceeding 12 billion yuan. It was also in this year that clopidogrel oral constant-release dosage forms were first included in the first batch of centralized procurement. With the 4+7 pilot and expansion in 2019, clopidogrel suffered a Waterloo, with sales in 2019-2021 falling by 6.27%, 59.19% and 3.11% year-on-year respectively. In 2021, the sales of this product exceeded 4.5 billion yuan, and in the first half of 2022, the sales exceeded 2 billion yuan, an increase of 8.85% year-on-year, and the annual sales are expected to achieve positive growth.
Sales of clopidogrel at terminals in public medical institutions in China (unit: 10,000 yuan)
Source: Mine.com Terminal Competitive Scheme of Public Medical Institutions in China
Source: Mine.com Terminal Competitive Scheme of Public Medical Institutions in China
Source: Mine.com Terminal Competitive Scheme of Public Medical Institutions in China
Source: Mine.com Terminal Competitive Scheme of Public Medical Institutions in China
